[go: up one dir, main page]

HRP20120818T1 - Method of treating atherosclerosis, dyslipidemias and related conditions - Google Patents

Method of treating atherosclerosis, dyslipidemias and related conditions Download PDF

Info

Publication number
HRP20120818T1
HRP20120818T1 HRP20120818TT HRP20120818T HRP20120818T1 HR P20120818 T1 HRP20120818 T1 HR P20120818T1 HR P20120818T T HRP20120818T T HR P20120818TT HR P20120818 T HRP20120818 T HR P20120818T HR P20120818 T1 HRP20120818 T1 HR P20120818T1
Authority
HR
Croatia
Prior art keywords
combination according
treatment
condition
pharmaceutically acceptable
combination
Prior art date
Application number
HRP20120818TT
Other languages
Croatian (hr)
Inventor
Kang Cheng
Gerard Waters
Gary O'neil
Kathleen Metters
Original Assignee
Merck Sharp & Dohme Corp.
Merck Canada Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120818(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp., Merck Canada Inc. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20120818T1 publication Critical patent/HRP20120818T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Claims (11)

1. Kombinacije spoja E, ili njegove farmaceutski prihvatljive soli ili solvata: [image] Spoj E nikotinske kiseline ili njene farmaceutski prihvatljive soli ili solvata i inhibitora HMG Co-A reduktaze.1. Combinations of compound E, or its pharmaceutically acceptable salt or solvate: [image] Compound E nicotinic acid or its pharmaceutically acceptable salts or solvates and HMG Co-A reductase inhibitors. 2. Kombinacija koja je u skladu s patentnim zahtjevom 1 gdje je inhibitor HMG-Co-A reduktaze odabran između lovastatina, simvastatina, dihidroksi otvorene kiseline simvastatina, pravastatina, fluvastatina, atorvastatina, pitavastatina i rosuvastatina.2. A combination according to claim 1 wherein the HMG-Co-A reductase inhibitor is selected from lovastatin, simvastatin, simvastatin dihydroxy open acid, pravastatin, fluvastatin, atorvastatin, pitavastatin and rosuvastatin. 3. Kombinacija koja je u skladu s patentnim zahtjevom 1 gdje je inhibitor HMG-Co-A reduktaze simvastatin.3. A combination according to claim 1 wherein the HMG-Co-A reductase inhibitor is simvastatin. 4. Kombinacija koja je u skladu s bilo kojim prethodnim patentnim zahtjevom za uporabu u liječenju.4. A combination according to any preceding patent claim for therapeutic use. 5. Kombinacija koja je u skladu s bilo kojim od patentnih zahtjeva 1 do 3 za uporabu u liječenju stanja odabranih između ateroskleroze, povećavanja serumskih razina HDL-a, liječenja dislipidemija, smanjivanja serumskih razina VLDL-a ili LDL-a, smanjivanja serumskih razina triglicerida i smanjivanja serumskih razina lipoproteina(a).5. A combination according to any one of claims 1 to 3 for use in the treatment of conditions selected from atherosclerosis, increasing serum HDL levels, treating dyslipidemias, reducing serum VLDL or LDL levels, reducing serum triglyceride levels and reduction of serum lipoprotein(a) levels. 6. Kombinacija koja je u skladu s bilo kojim od patentnih zahtjeva 1 do 3 za uporabu u liječenju stanja odabranih između ateroskleroze i dislipidemija.6. A combination according to any one of claims 1 to 3 for use in the treatment of conditions selected from atherosclerosis and dyslipidemia. 7. Kombinacija koja je u skladu s bilo kojim od patentnih zahtjeva 1 do 3 za uporabu u liječenju stanja iz patentnih zahtjeva 5 ili 6 u odsustvu značajnog crvenjenja.7. A combination according to any one of claims 1 to 3 for use in the treatment of the condition of claim 5 or 6 in the absence of significant redness. 8. Uporaba kombinacije koja je u skladu s bilo kojim od patentnih zahtjeva 1 do 3 za proizvodnju lijeka za liječenje stanja iz patentnih zahtjeva 5 ili 6.8. Use of a combination according to any one of claims 1 to 3 for the manufacture of a medicament for the treatment of the condition of claim 5 or 6. 9. Uporaba kombinacije koja je u skladu s bilo kojim od patentnih zahtjeva 1 do 3 za proizvodnju lijeka za liječenje stanja iz patentnog zahtjeva 5 ili 6 u odsustvu značajnog crvenjenja.9. Use of a combination according to any one of claims 1 to 3 for the manufacture of a medicament for the treatment of the condition of claim 5 or 6 in the absence of significant redness. 10. Uporaba farmaceutskog sastava sadržanog od kombinacije bilo kojeg od patentnih zahtjeva 1 do 3 i farmaceutski prihvatljivog nosača, za proizvodnju lijeka za liječenje stanja iz patentnog zahtjeva 5 ili 6.10. Use of a pharmaceutical composition consisting of a combination of any of claims 1 to 3 and a pharmaceutically acceptable carrier, for the production of a medicine for the treatment of a condition from claim 5 or 6. 11. Uporaba farmaceutskog sastava sadržanog od kombinacije bilo kojeg od patentnih zahtjeva 1 do 3 i farmaceutski prihvatljivog nosača, za proizvodnju lijeka za liječenje stanja iz patentnog zahtjeva 5 ili 6 u odsustvu značajnog crvenjenja.11. Use of a pharmaceutical composition comprising a combination of any one of claims 1 to 3 and a pharmaceutically acceptable carrier, for the production of a medicament for the treatment of the condition of claim 5 or 6 in the absence of significant redness.
HRP20120818TT 2003-05-15 2012-10-11 Method of treating atherosclerosis, dyslipidemias and related conditions HRP20120818T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47066503P 2003-05-15 2003-05-15

Publications (1)

Publication Number Publication Date
HRP20120818T1 true HRP20120818T1 (en) 2012-11-30

Family

ID=33476734

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20090424T HRP20090424T1 (en) 2003-05-15 2004-05-13 Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions
HRP20120818TT HRP20120818T1 (en) 2003-05-15 2012-10-11 Method of treating atherosclerosis, dyslipidemias and related conditions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HR20090424T HRP20090424T1 (en) 2003-05-15 2004-05-13 Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions

Country Status (44)

Country Link
US (4) US20040229844A1 (en)
EP (3) EP2116244B1 (en)
JP (2) JP4637833B2 (en)
KR (2) KR100806008B1 (en)
CN (3) CN102526735A (en)
AR (1) AR041089A1 (en)
AU (2) AU2004240597B2 (en)
BR (1) BRPI0410273A (en)
CA (1) CA2525772C (en)
CL (1) CL2004001056A1 (en)
CO (1) CO5630034A2 (en)
CR (2) CR8047A (en)
CY (2) CY1109476T1 (en)
DE (1) DE602004022036D1 (en)
DK (2) DK2116244T3 (en)
DO (1) DOP2004000907A (en)
EA (2) EA009744B1 (en)
EC (1) ECSP056156A (en)
ES (2) ES2392743T3 (en)
GE (2) GEP20084569B (en)
GT (1) GT200400098A (en)
HN (1) HN2004000171A (en)
HR (2) HRP20090424T1 (en)
IL (1) IL171962A (en)
IS (1) IS2708B (en)
JO (1) JO2564B1 (en)
MA (1) MA27835A1 (en)
ME (1) MEP60108A (en)
MX (1) MXPA05012272A (en)
MY (1) MY140639A (en)
NO (1) NO20055957L (en)
NZ (2) NZ543399A (en)
PA (1) PA8603201A1 (en)
PE (1) PE20050552A1 (en)
PL (2) PL2116244T3 (en)
PT (2) PT2116244E (en)
RS (3) RS20120499A1 (en)
SG (1) SG153667A1 (en)
SI (2) SI1624871T1 (en)
TN (1) TNSN05290A1 (en)
TW (2) TWI334354B (en)
UA (1) UA89615C2 (en)
WO (1) WO2004103370A1 (en)
ZA (1) ZA200508288B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094830A2 (en) * 2001-05-23 2002-11-28 Merck Frosst Canada & Co. DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
ES2582942T3 (en) 2004-10-08 2016-09-16 Forward Pharma A/S Pharmaceutical controlled release compositions comprising a fumaric acid ester
PE20060949A1 (en) 2004-12-23 2006-10-11 Arena Pharm Inc FUSED DERIVATIVES OF PIRAZOLE AS NIACIN RECEPTOR AGONISTS
US8165517B2 (en) * 2005-01-19 2012-04-24 The Trustees Of The University Of Pennsylvania Methods for identifying inhibitors of vascular injury
US20080139604A1 (en) * 2005-02-17 2008-06-12 Shaun Fitzpatrick Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
JP2008538277A (en) * 2005-02-18 2008-10-23 アリーナ ファーマシューティカルズ， インコーポレイテッド Compositions and methods for the treatment of lipid related disorders
AU2006247695B2 (en) * 2005-05-17 2012-08-09 Merck Sharp & Dohme Corp. Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP2009507791A (en) * 2005-08-29 2009-02-26 メルク エンド カムパニー インコーポレーテッド Niacin receptor agonists, compositions containing such compounds, and methods of treatment
RU2008112313A (en) * 2005-09-01 2009-10-10 Эррэй Биофарма Инк. (Us) COMPOUNDS RAF INHIBITORS AND WAYS OF THEIR APPLICATION
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
KR20080081321A (en) * 2005-12-21 2008-09-09 쉐링 코포레이션 Combination of H3 antagonist / reverse agonist and appetite suppressant
EP1962835A2 (en) * 2005-12-21 2008-09-03 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
CN101400682A (en) * 2006-01-20 2009-04-01 先灵公司 Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
US20080076750A1 (en) * 2006-09-15 2008-03-27 Aslanian Robert G Azetidinone Derivatives and Methods of Use Thereof
MX2009002924A (en) 2006-09-15 2009-05-28 Schering Corp Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders.
WO2008033464A2 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
WO2008097535A2 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
CN101559058B (en) * 2008-04-16 2011-07-20 北京本草天源药物研究院 Pharmaceutical composition for treating dyslipidemia
RU2010151944A (en) * 2008-05-20 2012-06-27 Серенис Терапьютикс С.А. (Fr) Niacin and NSAIDs for Combination Therapy
WO2010030360A1 (en) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
US20110165239A1 (en) * 2008-09-24 2011-07-07 Laman Alani Pharmaceutical compositions of atorvastatin
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379063B2 (en) 2009-01-09 2021-02-24 Fwp Ip Aps Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
JP2013522307A (en) 2010-03-16 2013-06-13 アベンティス・ファーマスーティカルズ・インコーポレイテツド Substituted pyrimidines as prostaglandin D2 receptor antagonists
EP2547672A1 (en) 2010-03-16 2013-01-23 Aventis Pharmaceuticals Inc. Substituted pyrimidines as prostaglandin d2 receptor antagonists
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (en) * 1971-08-13 1973-02-12 Hoffmann La Roche POLYCYCLIC COMPOUNDS
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
GB2076242B (en) 1977-09-30 1982-10-20 Rca Corp Television system scheduler
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DK149080C (en) 1980-06-06 1986-07-28 Sankyo Co METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
JP2648897B2 (en) 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
EP0821587A4 (en) * 1995-04-19 1999-05-19 Lipoprotein Technologies Inc Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
ATE219495T1 (en) 1995-10-31 2002-07-15 Schering Corp SUGAR SUBSTITUTED 2-AZETIDINONE USABLE AS HYPOCHOLESTERDENIC DRUGS
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
DK0814782T3 (en) 1995-12-22 2002-12-16 Nissan Chemical Ind Ltd Pharmaceutical preparation stabilized with a basic agent
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
DK1017390T3 (en) * 1997-07-31 2007-06-11 Kos Life Sciences Inc Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in a sustained-release form and an HMG-CoA reductase inhibitor in an immediate-release form
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
AU752059B2 (en) * 1997-10-27 2002-09-05 Dr. Reddy's Laboratories Limited Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
ES2244238T3 (en) 1998-12-07 2005-12-01 Schering Corporation PROCESS FOR SYNTHESIS OF AZETIDINONES.
EP1354604A1 (en) 1998-12-23 2003-10-22 G.D. Searle LLC. Combinations for cardiovascular indications
CA2367289C (en) 1999-04-05 2008-02-12 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(r)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl)]-4(s)-(4-hydroxyphenyl)-2-azetidinone
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
IT1306141B1 (en) * 1999-05-17 2001-05-30 Giampiero Valletta COMPOSITION FOR THE TREATMENT OF UREMIC ITCHING AND OF DEPRURED FORMS NOT RELATED TO ORGANIC INJURIES.
JP4292742B2 (en) 2000-03-09 2009-07-08 小野薬品工業株式会社 Indole derivatives, production methods and uses thereof
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP2002008186A (en) * 2000-06-23 2002-01-11 Mitsubishi Heavy Ind Ltd Vehicle type identification device
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (en) * 2000-09-13 2007-03-07 三洋電機株式会社 Video signal processing circuit
AU2002242910A1 (en) 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
WO2002094830A2 (en) * 2001-05-23 2002-11-28 Merck Frosst Canada & Co. DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
CA2459515A1 (en) 2001-09-07 2003-03-20 Kazuhiko Torisu Indole derivatives
AR038136A1 (en) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc CYCLALCANINDOLS WITH REPLACEMENT WITH FLUOR COMPOSITIONS CONTAINING THESE COMPOUNDS AND TREATMENT METHODS
ES2365985T3 (en) * 2002-03-19 2011-10-14 Ono Pharmaceutical Co., Ltd. CARBOXYL ACID COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS ACTIVE INGREDIENT.
ATE422884T1 (en) * 2002-06-03 2009-03-15 Novartis Pharma Gmbh USE OF SUBSTITUTED CYANOPYRROLIDINES FOR THE TREATMENT OF HYPERLIPIDEMIA
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (en) * 2005-07-01 2008-08-06 タキゲン製造株式会社 Stay

Also Published As

Publication number Publication date
AU2011200986A1 (en) 2011-03-31
DK2116244T3 (en) 2012-11-26
TWI341199B (en) 2011-05-01
ZA200508288B (en) 2008-08-27
JP4637833B2 (en) 2011-02-23
TNSN05290A1 (en) 2007-07-10
ES2392743T3 (en) 2012-12-13
EP2286816A1 (en) 2011-02-23
SG153667A1 (en) 2009-07-29
KR100806008B1 (en) 2008-02-26
EA011895B1 (en) 2009-06-30
HK1092722A1 (en) 2007-02-16
IS2708B (en) 2011-01-15
JP2010077151A (en) 2010-04-08
JP2006526030A (en) 2006-11-16
DOP2004000907A (en) 2004-11-30
TW200803844A (en) 2008-01-16
NZ543399A (en) 2009-02-28
MXPA05012272A (en) 2006-05-19
GEP20105025B (en) 2010-06-25
CN102526735A (en) 2012-07-04
KR20060012617A (en) 2006-02-08
DK1624871T3 (en) 2009-11-16
EP2116244A1 (en) 2009-11-11
PL1624871T3 (en) 2009-12-31
PL2116244T3 (en) 2013-01-31
GEP20084569B (en) 2008-12-25
CA2525772A1 (en) 2004-12-02
TW200503757A (en) 2005-02-01
PT1624871E (en) 2009-09-07
CY1113342T1 (en) 2016-06-22
CR9808A (en) 2008-07-29
CN100441184C (en) 2008-12-10
US20090233977A1 (en) 2009-09-17
US20100076002A1 (en) 2010-03-25
NZ572515A (en) 2010-07-30
WO2004103370A1 (en) 2004-12-02
RS20120498A1 (en) 2013-08-30
ES2328148T3 (en) 2009-11-10
PT2116244E (en) 2012-11-02
UA89615C2 (en) 2010-02-25
RS20050777A (en) 2008-04-04
AU2004240597B2 (en) 2011-01-06
US20110118292A1 (en) 2011-05-19
EP1624871A1 (en) 2006-02-15
CY1109476T1 (en) 2014-08-13
PE20050552A1 (en) 2005-08-06
KR100960749B1 (en) 2010-06-01
GT200400098A (en) 2005-03-03
BRPI0410273A (en) 2006-05-16
EP2116244B1 (en) 2012-08-08
AU2011200986B2 (en) 2012-11-08
EA200702674A1 (en) 2008-04-28
HRP20090424T1 (en) 2009-09-30
KR20080003470A (en) 2008-01-07
TWI334354B (en) 2010-12-11
AU2004240597A1 (en) 2004-12-02
SI1624871T1 (en) 2009-12-31
MY140639A (en) 2010-01-15
CN1787819A (en) 2006-06-14
MA27835A1 (en) 2006-04-03
CR8047A (en) 2006-07-14
RS52731B (en) 2013-08-30
EP1624871B1 (en) 2009-07-15
CA2525772C (en) 2011-03-15
US20040229844A1 (en) 2004-11-18
EA009744B1 (en) 2008-04-28
IS8071A (en) 2005-10-13
PA8603201A1 (en) 2005-02-04
SI2116244T1 (en) 2012-12-31
JO2564B1 (en) 2010-11-03
CN101559227A (en) 2009-10-21
IL171962A0 (en) 2006-04-10
DE602004022036D1 (en) 2009-08-27
ECSP056156A (en) 2006-04-19
CL2004001056A1 (en) 2005-03-28
MEP60108A (en) 2011-05-10
EA200501817A1 (en) 2006-06-30
RS20120499A1 (en) 2013-08-30
NO20055957L (en) 2006-02-14
AR041089A1 (en) 2005-05-04
CN101559227B (en) 2012-03-21
HN2004000171A (en) 2011-07-11
CO5630034A2 (en) 2006-04-28
IL171962A (en) 2012-06-28

Similar Documents

Publication Publication Date Title
HRP20120818T1 (en) Method of treating atherosclerosis, dyslipidemias and related conditions
HRP20241674T1 (en) 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS A PCSK9 INHIBITOR AND METHODS OF USE THEREOF
JP2022116083A5 (en)
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
Quirk et al. Rosuvastatin calcium
PT1509232E (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer`s disease
JP2002501887A5 (en) Use of a plasma triglyceride level lowering agent for the manufacture of a medicament for the treatment of Alzheimer's disease
WO2005046662A3 (en) Hdl-boosting combination therapy complexes
AU2014310371A2 (en) Compositions and therapeutic methods for accelerated plaque regression
UA89035C2 (en) Hydroxamic acid esters and pharmaceutical use thereof
JP2007277267A5 (en)
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
WO2005062824A3 (en) Anti-hypercholesterolemic compounds
SK1402004A3 (en) Process for preparing calcium salt forms of statins
GEP20022693B (en) Pyrimidine Derivatives as HMG-Coa Reductase Inhibitors
EP1699421A4 (en) SALTS OF QUINOLINONE COMPOUNDS ACCEPTABLE PHARMACEUTICALLY AND HAVING IMPROVED PHARMACEUTICAL PROPERTIES
AR022856A1 (en) OPEN ACID DIHIDROXI AND HMG-CO-A REDUCTASA INHIBITORS SALTS
TNSN08153A1 (en) Anti-hypercholesterolemic compounds
MX2007013133A (en) Inhibitors of microsomal triglyceride transfer protein and apo-b secretion.
RU2007143503A (en) METHODS FOR TREATING ATHEROSCLEROSIS
EP1275388A4 (en) TNF ALPHA INHIBITORS
RU2007149337A (en) A NEW METHOD FOR TREATING HYPERLIPIDEMIA
DE602006019710D1 (en) MAGNESIUM SALT OF HMG COA REDUCTASE INHIBITORS
WO2005058310A3 (en) Use of stating for the treatment of metabolic syndrome
JP2008513379A5 (en)